Genome-wide association study identifies common genetic variants associated with salivary gland carcinoma and its subtypes.
»
Genome-wide association study identifies common genetic variants associated with salivary gland carcinoma and its subtypes.
BACKGROUND salivary gland carcinoma (SGCs) is a rare malignancy with unknown etiology. The purpose of this research is to identify genetic variants modifying the risk of SGC and major subtypes: adenoid cystic carcinoma and mucoepidermoid carcinoma.
METHOD The author conducted a genome-wide association study in 309 cases defined SGC and 535 cancer-free controls. A single-nucleotide polymorphism (SNP) discovery -level studies conducted in non-Hispanic white individuals was followed by a replication study on Hispanic individuals. A logistic regression analysis was applied to calculate the odds ratio (OR) and 95% confidence intervals (95% CI). A meta-analysis of the results is done.
RESULTS A genome-wide significant association with SGC in non-Hispanic white individuals detected in the coding SNP in CHRNA2 (cholinergic receptor, nicotinic, alpha 2 [neuronal]) (OR, 8.55; 95% CI, 4.53 to 16.13 [ P = 3.6 × 10 (-11)]), OR4F15 (olfactory receptor, family 4, subfamily M, member 15) (OR, 5.26; 95% CI, 3.13 to 8.83 [P = 3 , 5 × 10 (-10)]), ZNF343 (zinc finger protein 343) (OR, 3.28; 95% CI, 2.12 to 5.07 [P = 9.1 × 10 (-8)]), and PARP4 (poly (ADP-ribose) polymerase family, member 4) (OR, 2:00; 95% CI, 1.54 to 2.59 [P = 1.7 × 10 (-7)]).
Meta-analysis of a cohort of non-Hispanic white and Hispanic identified another significant genome-wide SNP in ELL2 (meta-OR, 1.86; 95% CI, 1.48 to 2.34 [P = 1.3 × 10 (-7 )]). most of the risk allele enriched in mucoepidermoid carcinoma, in which the SNP in CHRNA2, OR4F15, and ZNF343 had an OR of 15.71 (95% CI, 6.59 to 37.47 [P = 5.2 × 10 (-10)]), 15.60 (95% CI, 6.50 to 37.41 [P = 7.5 × 10 (-10)]), and 6.49 (95% CI, 3.36 to 12.52 [P = 2.5 × 10 (-8)]), respectively. None of these SNPs maintained a significant relationship with adenoid cystic carcinoma.
CONCLUSION To the best of the authors’ knowledge, this is the first study to identify SNPs associated with the risk panel SGC. Confirmation of these findings along with the functional analysis of SNPs identified necessary.
Genome-wide association study identifies common genetic variants associated with salivary gland carcinoma and its subtypes.
Prospective new biomarkers for Metastatic Colorectal Cancer: A Meta-analysis In Vitro Studies.
Colorectal cancer (CRC) is one of the most common cancers and deadly. Although many studies have evaluated the potential biomarkers for early diagnosis, biomarkers date have failed to reach an acceptable level of accuracy for distant metastases. In this paper, we performed a meta-analysis of gene sets of microarray studies in vitro and combine the results from this study with previously published data to validate the proteomics and advise potential prognostic for CRC metastases.
Two microarray data sets including 21 genes significant finding. Of these significant genes, ALDOA, IL8 (CXCL8), and PARP4 has strong potential as a potential prognostic. LAMB2, MCM7, CXCL23A, SERPINA3, ABCA3, ALDH3A2, and POLR2I also has potential. Other candidates are more controversial, perhaps because of the biological heterogeneity of tumor cells, which is a major obstacle to predict metastasis. In conclusion, we show meta-analysis approach and successfully advise potential biomarker ten for future investigations.
hepatocellular carcinoma (HCC), the most common type of liver cancer, is the third leading cause of cancer deaths worldwide related. The molecular mechanisms underlying the initiation and formation of HCC remains unclear. In this study, we performed exome sequencing using a tumor and normal tissue of 3 hepatitis B virus (HBV) -positive BCLC stage
Description: A polyclonal antibody against PARP4. Recognizes PARP4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100
Description: A polyclonal antibody against PARP4. Recognizes PARP4 from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000
A patients with HCC. bioinformatics analysis performed to find candidate somatic protein-altering mutations. Eighty validated deleterious mutations and 59 genes were reported associated mutations in HBV HCCS for the first time here.
